Washington Puts the Brakes on U.S. Money Flow to China’s Biotech Boom

On Thursday night, the Trump administration slipped a draft rule into the public record that could rewrite the financial relationship between American drugmakers and China’s fast‑growing biotech sector. In plain English, the Treasury Department wants to stop U.S. investors from putting money into Chinese biotech companies—or even the factories that churn out the lab‑gear they need.

That sounds dramatic, and it is. The proposal is the latest effort to enforce the Comprehensive Outbound Investment National Security Act, or COINS, a law that already bars U.S. capital from areas like semiconductors, artificial intelligence and quantum computing. Adding “biotechnology” to that list puts an industry that has become a strategic priority for both sides of the Pacific under a new layer of scrutiny.

What’s odd, though, is the exemption carved out for “rights‑to‑medicines.” In practice, it means an American pharma can still purchase the patents, licenses or even the finished product that was invented in China, as long as the transaction isn’t a direct equity investment. The nuance feels like a footnote, but for companies that rely on Chinese innovation pipelines it could be a lifeline.

Industry reaction has been a mix of grumbles and guarded relief. Executives at several big‑pharma houses whispered to reporters that the rule feels “overly aggressive,” especially given how intertwined U.S. and Chinese research collaborations have become over the past decade. At the same time, a few senior leaders noted that the carve‑out for drug‑rights could preserve access to promising candidates that are already in early‑stage trials.

“We’ve built a lot of our pipeline on discoveries that originated in China,” said a senior R&D officer at a multinational company who asked to remain anonymous. “If we suddenly lose the ability to fund those partners, we risk slowing down the very drugs that could treat rare diseases and cancers.”

Other voices in Washington, particularly from the National Security Council, argue that the move is less about economics and more about safeguarding critical technologies. Biotech tools—think gene‑editing platforms, high‑throughput screening robots, and proprietary cell‑culture media—can be dual‑use, potentially feeding both life‑saving therapies and bioweapon research.

Critics, however, point out that the rule’s language is vague. The Treasury’s own guidance says “financial transactions” are prohibited, but it does not clearly define whether licensing fees, milestone payments or royalty streams fall under that umbrella. Legal scholars warn that ambiguous wording could trigger a flurry of lawsuits, leaving companies uncertain about where the line is drawn.

For now, the rule is just a proposal. The Treasury says it will accept public comments for the next 60 days before finalizing anything. Already, lobbyists from the biotech sector have filed a dozen formal comments, urging a narrower definition of “investment” and a clearer path for cross‑border collaborations that don’t compromise national security.

What does this mean for patients? Short‑term, probably little. Most drugs in the U.S. market today were developed years ago, and the rule doesn’t block existing products. Long‑term, though, the chill on fresh capital could slow the arrival of novel therapies that are currently being nurtured in Chinese labs.

In the end, the debate boils down to a classic tug‑of‑war: protect strategic tech assets, or keep the global pipeline of innovation humming. As the comment period unfolds, all eyes will be on how Washington balances those competing priorities.